C
AR-T is having a moment. The Food and Drug Administration looks poised to approve the first hot-wired white blood cell treatment from Novartis, promising to change the lives of patients with a particularly deadly form of cancer and usher in an entirely new definition of the word “drug.”
But scientists around the world are hardly standing pat in the glow of this success. Instead, they’re toiling to discover, refine, and re-invent cellular therapies for cancer in hopes of treating more tumor types, improving safety, and pushing the still-nascent field forward. Some of the most promising applications of the technology remain on the horizon — though plenty of challenges stand in the way.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
is this good news for people in remission from follicular lymphoma
There’s hope.
I was one of the first adults to receive CART019 at UPenn – before Novartis and UPenn solidified their contract. I am a seven-time leukemia (ALL) survivor thanks to all who believed and contributed!
The following is an article about me from Sence About Science:
http://www.senseaboutscienceusa.org/reporting-clinical-trial-results-changed-life/#health
More info on my website:
https://nicolegularte.wordpress.com/2016/04/26/cancer-the-future-immunotherapy/